Post-approval studies (Phase 4)Ended earlyNCT00972543What this trial is testingRaptiva in Palm and Sole PsoriasisWho this might be right forChronic Plaque Psoriasis Merck KGaA, Darmstadt, Germany 6
Post-approval studies (Phase 4)Study completedNCT00932113What this trial is testingMechanism of Action Study for PsoriasisWho this might be right forPsoriasis Tufts Medical Center 33
Not applicableStudy completedNCT00678470What this trial is testingOpen Label Study of Alefacept Injections to Patients With Moderate to Severe PsoriasisWho this might be right forModerate to Severe Psoriasis University of California, San Francisco 18
Not applicableWithdrawnNCT01758705What this trial is testingPost Marketing Observational Study on Venezuelan Patients With PsoriasisWho this might be right forModerate to Severe Chronic Plaque Psoriasis AbbVie (prior sponsor, Abbott)
Large-scale testing (Phase 3)Study completedNCT02074982What this trial is testingEfficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type PsoriasisWho this might be right forChronic Plaque Type Psoriasis Novartis Pharmaceuticals 676
Testing effectiveness (Phase 2)Study completedNCT02905006What this trial is testingStudy to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque PsoriasisWho this might be right forChronic Plaque Psoriasis UCB Biopharma S.P.R.L. 250
Large-scale testing (Phase 3)Study completedNCT00679731What this trial is testingSafety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque PsoriasisWho this might be right forPsoriasis AbbVie (prior sponsor, Abbott) 317
Large-scale testing (Phase 3)Study completedNCT03066609What this trial is testingStudy of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type PsoriasisWho this might be right forPlaque Psoriasis Novartis Pharmaceuticals 543
Large-scale testing (Phase 3)Study completedNCT04930042What this trial is testingEfficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque PsoriasisWho this might be right forPsoriasis Alvotech Swiss AG 581
Large-scale testing (Phase 3)Study completedNCT00570986What this trial is testingA Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisWho this might be right forPlaque Psoriasis AbbVie (prior sponsor, Abbott) 1,465
Large-scale testing (Phase 3)Study completedNCT00674063What this trial is testingAssess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque PsoriasisWho this might be right forChronic Plaque Psoriasis Astellas Pharma Inc 78
Early research (Phase 1)Study completedNCT01836939What this trial is testingSafety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque PsoriasisWho this might be right forPsoriasis Mark Lebwohl 8
Not applicableStudy completedNCT00096928What this trial is testingEvaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)Who this might be right forPsoriasis Genentech, Inc. 1,846
Not applicableStudy completedNCT01076192What this trial is testingStudy of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)Who this might be right forModerate-to-severe Chronic Plaque Psoriasis AbbVie (prior sponsor, Abbott) 547
Testing effectiveness (Phase 2)Study completedNCT00601107What this trial is testingEvaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe PsoriasisWho this might be right forModerate to Severe Chronic Plaque Psoriasis Genzyme, a Sanofi Company 111
Large-scale testing (Phase 3)Study completedNCT03412747What this trial is testingEvaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisWho this might be right forChronic Plaque PsoriasisModerate to Severe Plaque Psoriasis UCB Biopharma SRL 478
Large-scale testing (Phase 3)Study completedNCT01729754What this trial is testingEvaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)Who this might be right forPlaque Psoriasis Sun Pharmaceutical Industries Limited 1,090
Testing effectiveness (Phase 2)Study completedNCT01071252What this trial is testingA Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type PsoriasisWho this might be right forChronic Plaque-type Psoriasis Novartis Pharmaceuticals 125
Large-scale testing (Phase 3)Study completedNCT03849404What this trial is testingEfficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque PsoriasisWho this might be right forPlaque Psoriasis Alvotech Swiss AG 413
Testing effectiveness (Phase 2)Study completedNCT02908347What this trial is testingStudy to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis PatientsWho this might be right forPsoriasisPlaque Psoriasis MetrioPharm AG 46